linjc16/ctgov huggingface dataset:
The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

Study Overview
=================
Brief Summary
-----------------
Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

Detailed Description
-----------------
Biliary cancer ranked fifth in all gastrointestinal malignant cancer. Epidemiological surveys showed a significant increasing trend in recent years. How can make an early diagnosis of bile duct cancer as well as prognostic evaluation and efficacy monitoring, has become the hotspot. liquid biopsy, which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation. cf-DNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the cf-DNA originates from tumoral tissue. This, and the fact that cf-DNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. And we call the cf-DNA of tumor as ct-DNA. Peripheral blood mononuclear cells (PBMC) is any peripheral blood cell having a round nucleus. These cells can be extracted from whole blood using ficoll, a hydrophilic polysaccharide. PBMC contains genetic material of tumor and may be applied as a biomarker. This study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

Official Title
-----------------
The Role of ctDNA and PBMC as Biomarkers in Diagnostic, Efficacy Monitoring and Prognostic Evaluation of Biliary Tract Cancer

Conditions
-----------------
Biliary Tract Neoplasms

Intervention / Treatment
-----------------
* Procedure: surgery or biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected biliary tract cancer Age from 18 - 70 years No serious organic and mental illness; Exclusion Criteria: Pregnancy No pathologic result Suffering other malignancies at the same time.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others） | Sensitivity and specificity | intraoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor status （worse/ maintain/ better） | the level of ct-DNA compared with the tumor burden | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biomarkers, Neoplasms
Optical Coherence Pachymetry to Evaluate Central Corneal Ablation Depth in Myopic Femtosecond Laser in Situ Keratomileusis

Study Overview
=================
Brief Summary
-----------------
Prospective study aiming to measure central ablation depth during excimer laser surgery in myopic patients operated with femtosecond laser assisted LASIK with intraoperative OCP, before and after laser ablation. This measurement will be compared with pre and 1 month postoperative topography differential pachymetric measurements.

Official Title
-----------------
Optical Coherence Pachymetry (OCP) to Evaluate Central Corneal Ablation Depth in Myopic Femtosecond Laser in Situ Keratomileusis (LASIK)

Conditions
-----------------
Myopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years old undergoing refractive surgery with LASIK with myopic or compound myopic astigmatism ametropia without irregular cornea and topographical sign of keratoconus preoperative corneal thickness compatible with LASIK Exclusion Criteria: hyperopia opposition to participate in the study no health insurance coverage patient under legal protection pregnant or breastfeeding patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| depth of central corneal ablation | measured in microns with OCP | 1 month after surgery |
Evaluation of Mineral Absorption in Infants Fed Infant Formula

Study Overview
=================
Brief Summary
-----------------
This clinical trial will help determine if prebiotics can increase mineral absorption in babies

Conditions
-----------------
Mineral Absorption in the Urine

Intervention / Treatment
-----------------
* Other: Infant Formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton Term infant Birth weight of 2500 g or more 56-70 days of age Signed informed consent Consuming a cow's milk-based infant formula for at least 24 hours. Exclusion Criteria: History of underlying disease or congenital malformation which, in the opinion of the Investigator, is likely to interfere with the normal growth and development or the evaluation of the mineral absorption of the participant Use of multiple vitamin and mineral supplements prior to enrollment. Evidence of formula intolerance or poor intake at time of randomization

Ages Eligible for Study
-----------------
Minimum Age: 56 Days
Maximum Age: 70 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cow milk-based infant formula with prebiotic blend<br> | Other: Infant Formula<br> <br> |
| Placebo Comparator: Marketed Cow milk-based infant formula<br> | Other: Infant Formula<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the amount of minerals in the urine |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the amount of vitamins and minerals in the blood |  |  |
Analyzing Genes That May Increase the Risk of Developing High Blood Pressure

Study Overview
=================
Brief Summary
-----------------
High blood pressure is one of the most common health problems in the United States. Genetic variations may cause some people to be more susceptible to developing high blood pressure. This study will identify variations in genes known to play a part in the development of high blood pressure.

Detailed Description
-----------------
High blood pressure affects nearly one third of all individuals in the United States. It is especially common in African Americans, with more than 40% of African Americans diagnosed with this condition. High blood pressure usually develops earlier in life and is more severe in African Americans than in other racial or ethnic groups. Many factors can cause high blood pressure, including stress, diet, diabetes, kidney disease, or obesity. Previous studies have also shown that genetic variations on two regions of chromosomes 6 and 21 may predispose some people to develop high blood pressure. Admixture mapping is a type of genetic analysis that aims to identify disease-causing genetic variations across different populations of people. Using admixture mapping, this study will examine previously collected genetic samples from African American participants in the Family Blood Pressure Program (FBPP) study and from African American, Mexican American, Nigerian, and Jamaican participants enrolled in other clinical studies. Study researchers will analyze the samples to identify and characterize genetic variations that are associated with an increased risk of high blood pressure in the African American population, as well as other racial and ethnic groups.

Official Title
-----------------
Fine Mapping of Hypertension Genes Detected by Admixture Mapping in the FBPP

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participated in the FBPP study (African American [800 people with high blood pressure and 800 control group participants] and Mexican American participants) Participated in the American Family Study (African American participants) Participated in the Phenotyping Study (African American, Nigerian, and Jamaican participants)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic variations |  | Measured through admixture mapping genetic analysis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
High Blood Pressure
Infections After Renal Transplantation: Diseases Pattern in Hong Kong

Study Overview
=================
Brief Summary
-----------------
Infections are the most feared complications developing in patient who had had kidney transplantation. The aim of this study is to document the local disease pattern among this group of patients.

Official Title
-----------------
Infections After Renal Transplantation: Diseases Pattern in Hong Kong

Conditions
-----------------
Kidney Transplantation, Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All living-related or cadaveric renal transplantation episodes (including preemptive ones) performed in the Hong Kong Special Administration Region (HKSAR), Mainland China or overseas during the period 1/1/2000 to 30/6/2005 Exclusion Criteria: multiple organ recipients, incomplete records and lost to follow-up, including those cases who have been taken over by other renal centres

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infections
A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns

Study Overview
=================
Brief Summary
-----------------
Burn injuries can affect how well you are able to perform daily activities. The reason this study is being done is to find out if aerobic exercise helps burn patients recover function, strength and stamina. Participants will come to Johns Hopkins Bayview Medical Center, Burn Rehabilitation Gym for treadmill exercise sessions 3 days per week for 12 weeks. Participants will be tested for strength and stamina before the start of the 12 week program, at the end of the 12 week program, as well as 6 months, 1 year and 2 years after the end of the 12 week program. Patients who recently suffered a burn injury and who were discharged from the hospital in the past six months may be eligible to participate.

Official Title
-----------------
A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns

Conditions
-----------------
Deconditioning Among Survivors of Severe Burns

Intervention / Treatment
-----------------
* Behavioral: Augmented Exercise Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who recently suffered a burn injury and who were discharged from the hospital in the past six months may be eligible to participate Exclusion Criteria: History of heart-related health problems Foot burns

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Exercise<br> | Behavioral: Augmented Exercise Program<br>* 12 week (3 x per week) exercise prescription<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal Oxygen Consumption (VO2 max) |  | 2 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burn injuries, exercise
Comparison of 6% Hydroxyethyl Starch 130/0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass

Study Overview
=================
Brief Summary
-----------------
Comparison of 6% hydroxyethyl starch 130/0.4 with 5% albumin as priming solution for cardiopulmonary bypass

Conditions
-----------------
Mitral Valvular Heart Disease

Intervention / Treatment
-----------------
* Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mitral valvular heart disease Exclusion Criteria: Status of Infection Re-operation Liver failure Renal disease Administration of steroid
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HES 130/0.4<br> | Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin<br>* Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass<br>|
| Active Comparator: 5% albumin<br> | Drug: 6% hydroxyethyl starch 130/0.4 and 5% albumin<br>* Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the pure effect of priming solutions |  | after CPB |
Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Vitamin D3 (24,000 IU Vitamin D3 , qd) after oral administration in healthy adult volunteers.

Detailed Description
-----------------
The number of patient is thirty-six. Patients were randomly assigned either a Vitamin D3 tablet(24,000 IU Vitamin D3, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second or DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) first, Vitamin D3 tablet(24,000 IU Vitamin D3 , qd) second.

Official Title
-----------------
Randomized, Open-label Crossover Study to Evaluate Comparative Pharmacokinetics of Vitamin D3 Between DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 Tablet) and a 24,000 IU Vitamin D3 in Healthy Adult Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Vitamin D3
* Drug: DP-R206


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 to 55 years of healthy volunteers Exclusion Criteria: Hypersensitivity Reaction about Ibandronate or other drugs(aspirin, antibiotics)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vitamin D3<br> | Drug: Vitamin D3<br>* administration of Vitamin D3 24,000 IU<br>|
| Experimental: DP-R206<br> | Drug: DP-R206<br>* administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of pharmacokinetics | Cmax, AUClast | 24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of pharmacokinetics | AUCinf, tmax, t½β | 24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose |
Herbal Treatment of Hepatitis C in Methadone Maintained Patients

Study Overview
=================
Brief Summary
-----------------
Hepatitis C (HCV) is a chronic viral illness leading to progressive liver damage that has emerged as a major public health issue in the United States. While HCV affects all population groups, individuals with a history of intravenous drug use form the largest known risk group. Between 90 and 100 percent of long term intravenous drug use will eventually test positive for HCV, and there is substantial risk that even short term experimentation will result in infection. Studies suggest that HCV will be the major cause of cirrhosis and liver cancer in the next century. Currently, approved therapy includes recombinant interferons, which lead to sustained remission in a minority of patients. However, patients abusing other substances, including alcohol, are not eligible for interferon therapy. The need for investigation into other potential therapies is clear. Current practice patterns in the Far East include the use of traditional herbal remedies for symptomatic chronic viral hepatitis. This study is intended to examine the effect of commonly used herbal remedies for the treatment of symptomatic HCV.

Official Title
-----------------
Herbal Treatment of Hepatitis C in Methadone Maintained Patients

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Drug: Herbal remedies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English speaking/reading Serum positive for HCV virus by PCR Elevated alanine transferase (ALT) within 6 months of the Entry Visit, unattributable to causes other than HCV Liver biopsy within 2 years of entry confirming that the histological diagnosis is consistent with chronic HCV Laboratory parameters available at the Entry Visit including CBC, differential, and platelet count.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Herbal remedies|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique

Study Overview
=================
Brief Summary
-----------------
Recent studies indicate that infusing 300 milliliters of water (in lieu of air) into the rectum and left colon through the colonoscope as it is being inserted during a colonoscopy examination can allow easier endoscope advancement. This method may prevent stretching of the colon, and ultimately reduce pain induced during colonoscopy. Improvements in patient comfort and cooperation, may increase the efficiency and success rate of complete colonoscopy. The purpose of the study is to test the efficacy of the water immersion technique in patients colonoscopy.

Official Title
-----------------
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique

Conditions
-----------------
Colonoscopy, Digestive System, Endoscopy, Gastrointestinal Disease

Intervention / Treatment
-----------------
* Procedure: water immersion colonoscopy
* Procedure: standard air colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presentation for colonoscopy male age 18 or older Exclusion Criteria: women known inflammatory bowel disease presentation for emergency colonoscopy history of partial colectomy chronic narcotic or benzodiazepine use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Water Immersion Colonoscopy<br>Water Immersion Colonoscopy | Procedure: water immersion colonoscopy<br>* instillation of 300cc of water in the rectum<br>|
| Active Comparator: Standard Air Colonoscopy<br>Standard Air Colonoscopy | Procedure: standard air colonoscopy<br>* air instillation in colon for visualization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colonoscopy Success With Minimal Sedation |  | At the time of the procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Cecum |  | At the time of the procedure | 
| Patient Satisfaction | Patient satisfaction was measured on a scale of 1 (best) to 7 (worst). | At the time of the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy, diagnostic techniques, digestive system, endoscopy, gastrointestinal